Lobe Sciences Announces Launch of Preclinical Study in Collaboration with the University of Miami Miller School of Medicine

(MENAFN – Newsfile Corp) Lobe Sciences Announces Launch of Preclinical Study in Collaboration with the University of Miami Miller School of Medicine

Vancouver, British Columbia–(Newsfile Corp. – November 30, 2020) – Lobe Sciences Ltd. (CSE: LOBE) (OTC Pink: GTSIF) (” Lobe ” or the ” Company “) is pleased to announce the launch of preclinical research studies using psilocybin and N-Acetylcysteine (” NAC “) for the treatment of mild traumatic brain injury/concussion (” mTBI “) with post-traumatic stress disorder (” PTSD “). The study is in collaboration with a multidisciplinary team of scientists and physicians at the University of Miami Miller School of Medicine under the lead of Michael E. Hoffer, M.D., professor of otolaryngology and neurological surgery.

NAC has been shown to be safe and efficacious in a phase I human clinical study in treating military personnel who had suffered mTBI. The initial research focus is to demonstrate the safety and efficacy of the combination of psilocybin and NAC using broadly accepted rodent models. Final results are expected in 2021. Once this is established, more specific work can examine dose response, medicine uptake, and medicine levels. The research team at the Miller School of Medicine has conducted prior studies involving NAC with mTBI and has a license from the United States Drug Enforcement Administration to conduct research using Schedule I controlled substances, which includes psilocybin.

The Miller School of Medicine is an internationally recognized leader in medical research, ranked No. 39 among the top medical schools in the nation by Blue Ridge Institute for Medical Research. In 2019, the medical school submitted 1,968 research proposals and was awarded $149 million in research funding from the National Institutes of Health (NIH).

Advances in neuro-diagnostic assessment have revealed mild traumatic brain injury (concussion) is more common than previously thought and potentially associated with a host of negative health outcomes. The Centers for Disease Control (” CDC “) estimates that there are 3 million emergency room visits and over 230,000 hospitalizations due to TBI in any given year in the United States alone. Also, at the same time there are 5.3 million Americans living with the effects of mTBI (a 53% increase over ten years ago). The World Health Organization calls traumatic brain injury a “silent epidemic” that affects over 70 million individuals across the world. The United States Department of Defense estimates that over 345,000 individuals are affected by mTBI and that 20% of all service members who deploy suffer mTBI. mTBI and PTSD are significant health care issues that often co-occur and impact each other.

Dr. Hoffer, the principal investigator on the study, said, “This a very important extension of our work with NAC and other medicines to identify new treatments for mTBI and PTSD. We are hopeful that this new combination of psilocybin with NAC will lead us to better solutions for those suffering from mTBI and/or PTSD.”

Maghsoud Dariani, Chief Science Officer of Lobe said, “We are very excited to begin the preclinical studies in collaboration with Dr.

Read more

Remdesivir Medicine Market Will Hit Big Revenues In Future | Sanofi, Gilead Sciences, GlaxoSmithKline – Press Release

Remdesivir Medicine Market Will Hit Big Revenues In Future | Sanofi, Gilead Sciences, GlaxoSmithKline

Remdesivir Medicine Comprehensive Study by Application (Ebola Virus Disease, Marburg Virus Infection, Possible COVID-19 Treatment), Administration (Oral, Intravenous), End-users (Hospitals, Clinics, Ambulatory Surgical Centers, Others), Distribution Channel (Online Channel, Offline Channel) Players and Region – Global Market Outlook to 2025.

Global Remdesivir Medicine Market Comprehensive Study is an expert and top to bottom investigation on the momentum condition of the worldwide Global Remdesivir Medicine industry with an attention on the Global market. The report gives key insights available status of the Global Remdesivir Medicine producers and is an important wellspring of direction and course for organizations and people keen on the business. By and large, the report gives an inside and out understanding of 2020-2025 worldwide Remdesivir Medicine Market covering extremely significant parameters.

Key Players in This Report Include,
Gilead Sciences, Inc. (United States), Hainan Haiyao Co., Ltd. (China), Sanofi S.A. (France), GlaxoSmithKline plc (United Kingdom) and Cipla (India)

Free Sample Report + All Related Graphs & Charts @: https://www.advancemarketanalytics.com/sample-report/128698-global-remdesivir-medicine-market

Brief Summary of Global Remdesivir Medicine:
Remdesivir medicine is an anti-viral medication being studied as a possible post-infection treatment for COVID-19 illness. This medicine is a nucleotide analog, specifically an adenosine analog, which inserts into viral RNA chains causing their premature termination. It was developed by Gilead Sciences as a treatment for Ebola virus disease and Marburg virus infections. It is an investigational antiviral compound undergoing clinical trials in China, the United States and the United Kingdom as a potential treatment for COVID-19. It is not yet licensed or approved anywhere globally and has not been demonstrated to be safe or effective for any use.

Market Drivers

  • Increased Prevalence of COVID-19 Illness
  • Highly Effective Anti-viral Medicine

 

Market Trend

  • High Demand for Coronavirus Disease Treatment

 

Restraints

  • Lack of Clinical Evidence for COVID-19 Treatment

 

Opportunities

  • Increasing Number of Patients affecting COVID-19
  • Growth in the Healthcare Industry

 

Challenges

  • Stringent Government Rules and Regulations

This research report represents a 360-degree overview of the competitive landscape of the Global Remdesivir Medicine Market. Furthermore, it offers massive data relating to recent trends, technological, advancements, tools, and methodologies. The research report analyzes the Global Remdesivir Medicine Market in a detailed and concise manner for better insights into the businesses.

Regions Covered in the Global Remdesivir Medicine Market:

  • The Middle East and Africa (South Africa, Saudi Arabia, UAE, Israel, Egypt, etc.)
  • North America (United States, Mexico & Canada)
  • South America (Brazil, Venezuela, Argentina, Ecuador, Peru, Colombia, etc.)
  • Europe (Turkey, Spain, Turkey, Netherlands Denmark, Belgium, Switzerland, Germany, Russia UK, Italy, France, etc.)
  • Asia-Pacific (Taiwan, Hong Kong, Singapore, Vietnam, China, Malaysia, Japan, Philippines, Korea, Thailand, India, Indonesia, and Australia).


Enquire for customization in Report @ https://www.advancemarketanalytics.com/enquiry-before-buy/128698-global-remdesivir-medicine-market

The research study has taken the help of graphical presentation techniques such as infographics, charts, tables, and pictures. It provides guidelines for both established players and new entrants in the Global Remdesivir Medicine Market.

The detailed elaboration of the Global Remdesivir Medicine Market has been provided by applying industry analysis techniques such

Read more

ZYUS Life Sciences Strengthens Leadership in Evidence-Based Medicine with Appointment of Clinical Advisory Committee

SASKATOON, Saskatchewan–(BUSINESS WIRE)–ZYUS Life Sciences Inc. (“ZYUS”), a Canadian life sciences company leading scientific research and development in phyto-therapeutics, is pleased to announce the formation of a Clinical Advisory Committee to provide strategic advice and guidance on ZYUS’ clinical trial programs. Five committee members have been appointed to the Clinical Advisory Committee, adding additional medical, scientific, and clinical expertise to its experienced leadership team. This announcement is an important step in ZYUS’ integrated clinical development program and supports the company’s ambitions to pioneer the next generation of life sciences through an evidence-based approach.

Chaired by ZYUS’ Chief Medical Officer, Dr. Lionel Marks de Chabris, a leading expert in chronic pain management and addictions medicine, the ZYUS Clinical Advisory Committee includes four initial committee members including Dr. Mary Lynch, Dr. David J. Shulkin, Dr. Cedric Francois and Dr. Alice Zwerling. As ZYUS scales its clinical trial programs, the Clinical Advisory Committee will work closely with the research team to provide input and guidance on clinical development strategies and evaluate the clinical trial progress.

Each of the named Clinical Advisory Committee members bring remarkable medical leadership and expertise to their advisory roles. Dr. Mary Lynch ranks among North America’s leading experts in pain management. She is a Professor in the Departments of Anesthesiology, Pain Management and Perioperative Medicine, Psychiatry and Pharmacology in the Faculty of Medicine at Dalhousie University. In addition to being the founding director of the Canadian Consortium for the Investigation of Cannabinoids, Dr. Lynch co-chairs the Canadian Pain Strategy and is a member of the Royal College of Physicians and Surgeons Working Group on Pain Management. Her expertise in pain management is directly aligned with ZYUS’ research into the potential of phyto-therapeutics to manage chronic and neuropathic pain, and Dr. Lynch’s scientific research and thought-leadership in this space will provide valuable guidance to ZYUS’ clinical approach.

Providing cross-border expertise and widely respected medical leadership, Dr. David J. Shulkin will bring his decades of experience leading some of North America’s largest and most sophisticated medical networks to the ZYUS Clinical Advisory Committee. Dr. Shulkin previously served as the ninth Secretary of the US Department of Veterans Affairs and prior to holding that role, was appointed Under Secretary for Health by President Obama and confirmed unanimously by the U.S. Senate. In his role as Secretary of the U.S. Department of Veterans Affairs, he represented 21 million American veterans and was responsible for the country’s largest integrated health care system with over 1,200 sites of care. In addition to his roles in the public sector, Dr. Shulkin has served as the chief executive of multiple hospitals and health systems, and has been named as one of the “One Hundred Most Influential People in American Healthcare” by Modern Healthcare. Dr. Shulkin’s experience as a physician, hospital CEO and Secretary of the Department of Veterans Affairs provides unique insights into the medical, societal and political implications of ZYUS’ clinical trial programs.

The co-founder and Chief Executive Officer and President of Apellis Pharmaceuticals,

Read more